Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report)'s share price traded down 4.2% on Monday . The stock traded as low as $19.20 and last traded at $19.13. 105,106 shares were traded during mid-day trading, a decline of 72% from the average session volume of 378,351 shares. The stock had previously closed at $19.96.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on the company. HC Wainwright lifted their price target on Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. Robert W. Baird boosted their price objective on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday, June 16th. Finally, The Goldman Sachs Group began coverage on Enliven Therapeutics in a research note on Monday, June 16th. They set a "buy" rating and a $37.00 price objective for the company. Five analysts have rated the stock with a Buy rating, According to MarketBeat, Enliven Therapeutics has an average rating of "Buy" and a consensus price target of $41.20.
Get Our Latest Analysis on Enliven Therapeutics
Enliven Therapeutics Price Performance
The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -9.48 and a beta of 0.89. The business has a fifty day moving average of $20.11 and a 200 day moving average of $19.67.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. On average, equities research analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.
Insider Buying and Selling
In other news, CEO Samuel Kintz sold 5,000 shares of the company's stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $19.09, for a total transaction of $95,450.00. Following the sale, the chief executive officer owned 922,892 shares of the company's stock, valued at approximately $17,618,008.28. This represents a 0.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $20.63, for a total value of $67,047.50. Following the completion of the transaction, the chief financial officer directly owned 23,000 shares in the company, valued at $474,490. This trade represents a 12.38% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 85,234 shares of company stock worth $1,756,514 over the last ninety days. Insiders own 25.90% of the company's stock.
Hedge Funds Weigh In On Enliven Therapeutics
Several large investors have recently bought and sold shares of the business. GAMMA Investing LLC boosted its stake in Enliven Therapeutics by 3,058.1% in the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock valued at $53,000 after acquiring an additional 2,630 shares in the last quarter. Quantbot Technologies LP acquired a new position in Enliven Therapeutics in the first quarter valued at $60,000. BNP Paribas Financial Markets boosted its stake in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock valued at $75,000 after acquiring an additional 930 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Enliven Therapeutics by 194.3% in the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company's stock valued at $106,000 after acquiring an additional 3,490 shares in the last quarter. Finally, KLP Kapitalforvaltning AS boosted its stake in Enliven Therapeutics by 58.1% in the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company's stock valued at $136,000 after acquiring an additional 2,500 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Read More
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
